Healthcare | May 08, 2026
Vijaya Diagnostic Q4FY26 revenue jumps 27%, EBITDA margin expands to 43.5%
With robust FY26 growth, plans AI-led diagnostics and genomic testing expansion
With robust FY26 growth, plans AI-led diagnostics and genomic testing expansion
The deal positions MilliporeSigma at the center of commercial manufacturing for three breakthrough gene therapies targeting sickle cell disease, ?-thalassemia, and cerebral adrenoleukodystrophy
The event will bring together industrial leaders, technology providers, and policymakers to discuss real-world Industrial AI applications in Bangalore
These check-ups will be conducted through ESIC’s extensive network of hospitals, with a focus on early diagnosis, preventive healthcare, and continuous health monitoring
Successful inspection outcome strengthens company’s regulatory compliance and manufacturing standards in China
The standout story remains Wegovy, particularly its new oral formulation
FY26 revenue rises 17% to Rs. 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter
The company informed stock exchanges that the appellate authority has set aside the GST demand along with applicable interest and penalty
The company also announced a major portfolio shift, planning to divest its Immunodiagnostics business in China, a unit that generated approximately 6% of its fiscal 2025 revenue
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
Subscribe To Our Newsletter & Stay Updated
